1367874-96-1

Basic information

• Product Name: 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-N-methyl-1H-pyrrole-2-carboxamide
• Synonyms: 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-N-methyl-1H-pyrrole-2-carboxamide
• CAS NO: 1367874-96-1
• Molecular Weight: 583.733
• Mol File: 1367874-96-1.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-N-methyl-1H-pyrrole-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-N-methyl-1H-pyrrole-2-carboxamide(1367874-96-1)
• EPA Substance Registry System: 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-N-methyl-1H-pyrrole-2-carboxamide(1367874-96-1)

Safety Data

• Hazardous Substances Data: 1367874-96-1(Hazardous Substances Data)

Upstream product

• 1367830-46-3 methyl 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H pyrrole-2-carboxylate 
• 1367874-94-9 methyl 4-(4-isopropoxy-1-trityl-1H-pyrazolo[4,3-c]pyridine-3-yl)-1-isopropyl-1H-pyrrole-2-carboxylate 
• 1367874-93-8 3-iodo-4-isopropoxyl-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 1367874-83-6 methyl 4-bromo-1-isopropyl-1H-pyrrole-2-carboxylate 
• 1186647-69-7 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine 
• 1246350-27-5 4-chloro-3-iodo-1-trityl-1H-pyrazolo[4,3-c]pyridine 
• 871836-51-0 4-chloro-1H-pyrazolo [4,3-c]pyridine 
• 26452-80-2 2,4-dichloropyridine 
• 934-05-4 methyl 4-bromo-1H-pyrrole-2-carboxylate 
• 134031-24-6 2,4-dichloro-3-pyridine Carboxaldehyde 
• 1367874-95-0 4-(4-isopropoxy-1-trityl-1H-pyrzolo[4,3-c]pyridine-3-yl)-1-isopropyl-1H-pyrrole-2-carboxyilic acid 
• 593-51-1 methylamine hydrochloride 

Relevant articles and documents

PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts or esters thereof, (Formula I) wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7 -heterocycloalkyl; -CONR4R5; - NHCOR6; -C3-7-cycloalkyl,-NR3R6; -OR3; OH; NR4R5; and alkyl optionally substituted with a substituent selected from R11 and a group A; wherein said aryl, heteroaryl, fused aryl-C4-7 -heterocycloalkyl and C4-7-heterocycloalkyi are each optionally substituted with one or more substituents selected from C1-6-alkyl, C3-7-cycloalkyl, heteroaryl, C4-7-heterocycloalkyl, aryl and a group A, and said C1-6- alkyl, C3-7-cycloalkyl, heteroaryl, C4-7-heterocycloalkyl, and aryl substituents are in turn each optionally substituted with one or more groups selected from R11 and a group A; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, heteroaryl, heterocycloalkyi, fused aryl-C4-7-rheterocycloalkyl and halogen, wherein said C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, fused aryl-C4-7 -heterocycloalkyl and C4-7 -heterocycloalkyl are each optionally substituted with one or more substituents selected from R11 and A. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds